Zolbetuximab Combination Therapy: Global Efficacy and Safety Profile in CLDN18.2-Positive Advanced Gastric Cancer

　　1.Pivotal Efficacy Data:Redefining First-Line Treatment

　　Zolbetuximab(Brand name:Vyloy)is the first-in-class monoclonal antibody targeting the CLDN18.2 receptor.Its efficacy in first-line treatment for CLDN18.2-positive(defined as≥75%tumor cell staining)advanced gastric cancer is supported by two pivotal Phase III trials:SPOTLIGHT and GLOW.Results demonstrate that adding Zolbetuximab to standard chemotherapy(mFOLFOX6 or CAPOX)significantly improves both progression-free survival(PFS)and overall survival(OS)compared to chemotherapy alone.Specifically,the median OS in the combination arm reached 15 to 18 months versus 12 to 15 months with chemo alone,while median PFS was extended by approximately 1.5 to 2 months.The objective response rate(ORR)was approximately 50-55%with a complete response rate of 5-8%,outperforming chemotherapy monotherapy.

　　2.Durability of Response and Survival Benefit

　　While not curative,Zolbetuximab provides a durable survival benefit.The median duration of response is approximately 8 to 9 months,with about 30%of responders maintaining remission beyond 12 months.Long-term survival data indicates that roughly 35%of patients in the combination group survive beyond 24 months,a significant improvement over the 25%observed in the chemotherapy-only cohort,suggesting a meaningful tail-of-the-curve effect.

　　3.Real-World Feedback and Safety Management

　　Feedback from overseas patient communities is largely positive,with many reporting declines in tumor markers(e.g.,CA19-9,CA72-4)and tumor shrinkage,alongside improved performance status and appetite.However,adverse events impact adherence.Nausea(~85%),vomiting(~70%),and fatigue(~45%)are prevalent,mostly grade 1-2.Crucially,approximately 10%of patients discontinued treatment due to infusion reactions or intolerable gastrointestinal toxicity,which correlated with shorter OS.Therefore,proactive antiemetic prophylaxis and infusion rate management are critical to ensuring efficacy.

　　4.Predictive Biomarkers and Economic Access

　　Treatment benefit is strictly tied to CLDN18.2 expression intensity.Patients with≥75%of tumor cells showing moderate-to-strong staining derive the greatest benefit(HR=0.70),whereas those with 40-75%expression see diminished returns.Regarding access,Zolbetuximab remains a significant financial investment in most regions,as it is not yet widely reimbursed.Patients should conduct a thorough risk-benefit analysis with their oncologists prior to initiation.